Molecular cross-talk of IL-6 in tumors and new progress in combined therapy.

about

Molecular cross-talk of IL-6 in tumors and new progress in combined therapy.

Item

http://www.wikidata.org/entity/Q52336242

description

2018 nî lūn-bûn

@nan

2018年の論文

@ja

2018年学术文章

@wuu

2018年学术文章

@zh

2018年学术文章

@zh-cn

2018年学术文章

@zh-hans

2018年学术文章

@zh-my

2018年学术文章

@zh-sg

2018年學術文章

@yue

2018年學術文章

@zh-hant

name

Molecular cross-talk of IL-6 in tumors and new progress in combined therapy.

@en

Molecular cross-talk of IL-6 in tumors and new progress in combined therapy.

@nl

type

Item

label

Molecular cross-talk of IL-6 in tumors and new progress in combined therapy.

@en

Molecular cross-talk of IL-6 in tumors and new progress in combined therapy.

@nl

prefLabel

Molecular cross-talk of IL-6 in tumors and new progress in combined therapy.

@en

Molecular cross-talk of IL-6 in tumors and new progress in combined therapy.

@nl

P1476

Molecular cross-talk of IL-6 in tumors and new progress in combined therapy.

@en

P2093

Dian Ren

http://www.w3.org/2001/XMLSchema#string

Xiaohong Xu

http://www.w3.org/2001/XMLSchema#string

Yuxin Wang

http://www.w3.org/2001/XMLSchema#string

P275

Creative Commons Attribution-NonCommercial

P2860

Human SWI/SNF-associated PRMT5 methylates histone H3 arginine 8 and negatively regulates expression of ST7 and NM23 tumor suppressor genes

The reelin and GAD67 promoters are activated by epigenetic drugs that facilitate the disruption of local repressor complexes

Dangerous liaisons: STAT3 and NF-kappaB collaboration and crosstalk in cancer

Loss of p53 attenuates the contribution of IL-6 deletion on suppressed tumor progression and extended survival in Kras-driven murine lung cancer

IL-6 and Stat3 are required for survival of intestinal epithelial cells and development of colitis-associated cancer

Tumor-associated macrophage-derived IL-6 and IL-8 enhance invasive activity of LoVo cells induced by PRL-3 in a KCNN4 channel-dependent manner

Antitumor efficacy of the anti-interleukin-6 (IL-6) antibody siltuximab in mouse xenograft models of lung cancer.

JAK1 activates STAT3 activity in non-small-cell lung cancer cells and IL-6 neutralizing antibodies can suppress JAK1-STAT3 signaling

A high-affinity protein binder that blocks the IL-6/STAT3 signaling pathway effectively suppresses non-small cell lung cancer.

Penetration of interleukin-6 across the murine blood-brain barrier.

P304

669-675

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

review article

P356

10.1111/1759-7714.12633

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Zuoqing Song

P5008

ScienceSource

P577

2018-03-30T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

2018-06-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29603884

http://www.w3.org/2001/XMLSchema#string

P921

Aillse

peptide

P932

5983184

http://www.w3.org/2001/XMLSchema#string